A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)
A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)
Sponsor: Medikine, Inc.
Terminated
Corporate decision
Other Advanced or Metastatic Solid Tumors trials with similar outcome
Listed as NCT05716295, this PHASE1/PHASE2 trial focuses on Advanced or Metastatic Solid Tumors and remains terminated or withdrawn. Sponsored by Medikine, Inc., it has been updated 6 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medikine, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .